Jennifer Pavillard

Jennifer Pavillard has an extensive work experience in the field of regulatory affairs. Jennifer is currently serving as the Head of Regulatory Affairs and Vice President at ML Bio Solutions (a BridgeBio Company) since September 2022. Prior to this, they were the Head of Regulatory Affairs at CoA Therapeutics starting from December 2021. Jennifer also held positions at Origin Biosciences and BridgeBio as Vice President and Senior Director of Regulatory Affairs. Jennifer has also worked at TransCelerate BioPharma Inc., GSK, Shire, AstraZeneca, Sanofi-Aventis Dermatology, and Wyeth Pharmaceuticals S.A./N.V. in various regulatory roles. Their experience spans across nearly two decades, with a focus on global regulatory affairs.

Jennifer Pavillard attended the University of Maryland from 1985 to 1990, where they obtained a Bachelor of Science degree in Animal Sciences.